Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Osimertinib Plus Chemotherapy in EGFR-mutant Stage III NSCLC
NCT05011487Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Complete Lymph Node Clearance Rate at 12 weeks. Started Aug 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05011487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011487.